Torrent Pharma

3 published calls

• Antique Stock BrokingBUY18 Aug 2026

  —5,600—

  Revenue grew 55% YoY to INR 49bn, driven by strong performance in India and US generics. EBITDA margin expanded 90bps YoY to 33.8%.

• Motilal OswalNEUTRAL31 Jul 2026

  4,8904,730-3.3%

  Torrent Pharma delivered a better-than-expected 1QFY27 performance driven by domestic branded formulations and US generics, though valuation caps upside. We largely maintain our estimates and maintain our Neutral rating with a target price of INR4,730.

• ICICI SecuritiesHOLD31 Jul 2026

  4,8724,925+1.1%

  Torrent Pharma’s strong Q1FY27 performance was driven by robust traction in India, currency benefits, and strong US growth. Management raised FY27/28E EBITDA by 2-3% to factor in better margins, leading to a maintained HOLD rating with a revised target price of INR 4,925.

Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.